ArticleEBioMedicine2026
Genomic structural equation modelling of 12 cancers identifies a latent pan-cancer susceptibility factor and shared determinants of carcinogenesis.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCommon cancers share germline susceptibility, yet the genetic architecture of a truly pan-cancer component of carcinogenesis remains incompletely resolved.
methodsWe applied genomic structural equation modelling (gSEM) to genome-wide association studies (GWAS) summary statistics for 12 cancers (>600,000 European-ancestry cases) to separate a latent pan-cancer genetic factor from cancer-specific components, and then performed a multivariate GWAS of that factor. We conducted comprehensive downstream genetic, predictive, and functional analyses to characterise the resulting pan-cancer factor.
findingsWe identified 133 LD-independent loci associated with the pan-cancer factor, including eight loci not previously associated with any cancer phenotype. Pan-cancer genetic risk was concentrated in evolutionarily conserved regulatory DNA, with enrichment in promoter and enhancer annotations and tissue-relevant signals in mammary and uterine contexts. A pan-cancer polygenic risk score (PRS) derived from the latent-factor GWAS improved prediction of overall cancer in UK Biobank (Royston-Sauerbrei R
interpretationTogether, these results delineate a gSEM-derived pan-cancer genetic architecture, provide a cross-site PRS for overall cancer susceptibility, and nominate genes and circulating proteins for functional follow-up and prevention-oriented target discovery.
fundingNoncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China, and National Key Research and Development Program of China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.